In the clinical studies of IPASS (Mok et al., 2009), WJTOG3405 (Mitsudomi et al., 2010), and NEJ002 (Inoue et al., 2013), gefitinib showed longer PFS and higher ORR than those with traditional chemotherapy in EGFR-positive mutation-advanced NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.